M

Merus NV
D

MRUS

45.485
USD
1.15
(2.58%)
Market Closed
Volume
25,020
EPS
-4
Div Yield
-
P/E
-11
Market Cap
3,114,070,530
Related Instruments
    C
    CARA
    -0.01170
    (-3.57%)
    0.31600 USD
    M
    MRNS
    -0.00350
    (-1.13%)
    0.30490 USD
    O
    ONCS
    -0.01000
    (-0.44%)
    2.16000 USD
    P
    PBYI
    -0.57500
    (-19.23%)
    2.41500 USD
    P
    PRTA
    -2.100
    (-13.04%)
    14.000 USD
    S
    SCYX
    -0.06000
    (-4.76%)
    1.20000 USD
    T
    TNXP
    -0.00910
    (-6.53%)
    0.13030 USD
    More
News

Title: Merus NV

Sector: Healthcare
Industry: Biotechnology
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.